Novartis may have game-changing drug

September 2, 2014 7:55 PM

8 0

Novartis may have game-changing drug

Novartis is poised to change the way heart-failure patients are treated, if weekend reaction to data surrounding its experimental drug LCZ696 is any indication. The company released data at the European Society of Cardiology Congress that Jefferies analyst Jeffery Holford described in a Monday research note as “overwhelming and unambiguous efficacy.” Leerink's Seamus Fernandez wrote in a research note yesterday that a key opinion leader called the drug a game-changer.

The twice-daily oral blends neprilysin inhibitor sacubitril and the angiotensin II receptor blocker valsartan. The combination drug reduced cardiovascular mortality among patients with reduced ejection fraction by 20%, and reduced hospitalization for heart failure by 21%, compared to ACE-inhibitor e...

Read more

To category page

Loading...